<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777479/" ref="ordinalpos=2989&amp;ncbi_uid=5590735&amp;link_uid=PMC3777479" image-link="/pmc/articles/PMC3777479/figure/cjc-31-04-178-g002/" class="imagepopup">Figure 2.Niclosamide targets the Wnt/β-catenin, Notch, and mTORC1 pathways..  From: Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple <span class="highlight" style="background-color:">signaling</span> pathways of cancer stem cells. </a></div><br /><div class="p4l_captionBody">Niclosamide down-regulates the expression of Dishevelled-2 and inhibits the stabilization of β-catenin. Niclosamide also inhibits Notch signaling pathway and mTORC1. LRP, low-density lipoprotein-related protein receptor; IRS1, insulin receptor substrate 1; RTK, receptor tyrosine kinase.</div></div>